Svensson J - Search Results

1

The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.

Venizelos A, Elvebakken H, Perren A, Nikolaienko O, Deng W, Lothe IMB, Couvelard A, Hjortland GO, Sundlöv A, Svensson J, Garresori H, Kersten C, Hofsli E, Detlefsen S, Krogh M, Sorbye H, Knappskog S. Venizelos A, et al. Among authors: svensson j. Endocr Relat Cancer. 2021 Nov 11;29(1):1-14. doi: 10.1530/ERC-21-0152. Endocr Relat Cancer. 2021. PMID: 34647903 Free PMC article.

2

Individualised ¹⁷⁷Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.

Sundlöv A, Sjögreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, Tennvall J. Sundlöv A, et al. Among authors: svensson j. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1480-1489. doi: 10.1007/s00259-017-3678-4. Epub 2017 Mar 22. Eur J Nucl Med Mol Imaging. 2017. PMID: 28331954 Free PMC article. Clinical Trial.

3

Feasibility of simplifying renal dosimetry in ¹⁷⁷Lu peptide receptor radionuclide therapy.

Sundlöv A, Gustafsson J, Brolin G, Mortensen N, Hermann R, Bernhardt P, Svensson J, Ljungberg M, Tennvall J, Sjögreen Gleisner K. Sundlöv A, et al. Among authors: svensson j. EJNMMI Phys. 2018 Jul 5;5(1):12. doi: 10.1186/s40658-018-0210-2. EJNMMI Phys. 2018. PMID: 29974391 Free PMC article.

4

Bone Marrow Absorbed Doses and Correlations with Hematologic Response During ¹⁷⁷Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases.

Hagmarker L, Svensson J, Rydén T, van Essen M, Sundlöv A, Gleisner KS, Gjertsson P, Bernhardt P. Hagmarker L, et al. Among authors: svensson j. J Nucl Med. 2019 Oct;60(10):1406-1413. doi: 10.2967/jnumed.118.225235. Epub 2019 Mar 22. J Nucl Med. 2019. PMID: 30902877 Free PMC article.

5

Pituitary Function after High-Dose 177Lu-DOTATATE Therapy and Long-Term Follow-Up.

Sundlöv A, Sjögreen-Gleisner K, Tennvall J, Dahl L, Svensson J, Åkesson A, Bernhardt P, Lindgren O. Sundlöv A, et al. Among authors: svensson j. Neuroendocrinology. 2021;111(4):344-353. doi: 10.1159/000507761. Epub 2020 Apr 8. Neuroendocrinology. 2021. PMID: 32259830 Free PMC article. Clinical Trial.

6

Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE.

Warfvinge CF, Gustafsson J, Roth D, Tennvall J, Svensson J, Bernhardt P, Åkesson A, Wieslander E, Sundlöv A, Sjögreen Gleisner K. Warfvinge CF, et al. Among authors: svensson j. J Nucl Med. 2024 May 9:jnumed.123.266991. doi: 10.2967/jnumed.123.266991. Online ahead of print. J Nucl Med. 2024. PMID: 38724277

7

[177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney.

Swärd C, Bernhardt P, Ahlman H, Wängberg B, Forssell-Aronsson E, Larsson M, Svensson J, Rossi-Norrlund R, Kölby L. Swärd C, et al. Among authors: svensson j. World J Surg. 2010 Jun;34(6):1368-72. doi: 10.1007/s00268-009-0387-6. World J Surg. 2010. PMID: 20066413

8

Segmentation of Whole-Body Images into Two Compartments in Model for Bone Marrow Dosimetry Increases the Correlation with Hematological Response in ¹⁷⁷Lu-DOTATATE Treatments.

Hagmarker L, Svensson J, Rydén T, Gjertsson P, Bernhardt P. Hagmarker L, et al. Among authors: svensson j. Cancer Biother Radiopharm. 2017 Nov;32(9):335-343. doi: 10.1089/cbr.2017.2317. Epub 2017 Nov 10. Cancer Biother Radiopharm. 2017. PMID: 29125780

9

Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-Term Results of a Randomized Clinical Trial.

Elf AK, Andersson M, Henrikson O, Jalnefjord O, Ljungberg M, Svensson J, Wängberg B, Johanson V. Elf AK, et al. Among authors: svensson j. World J Surg. 2018 Feb;42(2):506-513. doi: 10.1007/s00268-017-4324-9. World J Surg. 2018. PMID: 29167951 Free PMC article. Clinical Trial.

10

Nephrotoxicity profiles and threshold dose values for [177Lu]-DOTATATE in nude mice.

Svensson J, Mölne J, Forssell-Aronsson E, Konijnenberg M, Bernhardt P. Svensson J, et al. Nucl Med Biol. 2012 Aug;39(6):756-62. doi: 10.1016/j.nucmedbio.2012.02.003. Epub 2012 Mar 24. Nucl Med Biol. 2012. PMID: 22445743

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,023 results

Search Page